HK1207642A1 - Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors c-met - Google Patents
Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors c-metInfo
- Publication number
- HK1207642A1 HK1207642A1 HK15108314.5A HK15108314A HK1207642A1 HK 1207642 A1 HK1207642 A1 HK 1207642A1 HK 15108314 A HK15108314 A HK 15108314A HK 1207642 A1 HK1207642 A1 HK 1207642A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- met
- tyrosine kinase
- kinase inhibitors
- pyridine derivatives
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012077924 | 2012-06-29 | ||
| PCT/CN2013/078592 WO2014000713A1 (en) | 2012-06-29 | 2013-07-01 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207642A1 true HK1207642A1 (en) | 2016-02-05 |
Family
ID=49782283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15108314.5A HK1207642A1 (en) | 2012-06-29 | 2015-08-27 | Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors c-met |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9617257B2 (ru) |
| EP (1) | EP2867223B1 (ru) |
| JP (1) | JP6059342B2 (ru) |
| KR (3) | KR101726555B1 (ru) |
| AU (1) | AU2013283993B2 (ru) |
| BR (1) | BR112014032745B1 (ru) |
| CA (1) | CA2878049C (ru) |
| ES (1) | ES2698511T3 (ru) |
| HK (1) | HK1207642A1 (ru) |
| IN (1) | IN2015DN00372A (ru) |
| RU (1) | RU2619130C2 (ru) |
| SG (1) | SG11201408750VA (ru) |
| TW (1) | TWI520962B (ru) |
| WO (1) | WO2014000713A1 (ru) |
| ZA (1) | ZA201500344B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106279147A (zh) | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US10577364B2 (en) | 2015-07-20 | 2020-03-03 | Betta Pharmaceuticals Co., Ltd | Crystalline form of fused pyridine derivative's maleate and uses thereof |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| CR20180413A (es) | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
| WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3064975A1 (en) * | 2017-05-26 | 2018-11-29 | Glenmark Pharmaceuticals S.A. | Novel inhibitors of map4k1 |
| JP7131837B2 (ja) * | 2017-06-19 | 2022-09-06 | アビスコ セラピューティクス カンパニー リミテッド | Ｃｓｆ－１ｒ阻害活性を有するアザアリール誘導体、その製造方法および応用 |
| CN109988108B (zh) * | 2017-12-29 | 2022-04-29 | 江苏豪森药业集团有限公司 | 一种卡博替尼的制备方法 |
| MX2021006982A (es) * | 2018-12-14 | 2021-09-10 | Beta Pharma Inc | Compuestos sustituidos con organofosforo como inhibidores de c met, y usos terapeuticos de los mismos. |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TWI812302B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Ｌｇ化學股份有限公司 | 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物 |
| EP4289427A1 (en) * | 2022-06-10 | 2023-12-13 | Anagenesis Biotechnologies | Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005005389A2 (en) * | 2003-07-07 | 2005-01-20 | Merck Patent Gmbh | Malonamide derivatives |
| DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CA2572331A1 (en) * | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
| KR101257343B1 (ko) * | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 |
| EP1827434B1 (en) * | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| CN101248080B (zh) | 2005-05-20 | 2012-09-05 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
| EP2079738A2 (en) * | 2006-10-27 | 2009-07-22 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| RU2011119478A (ru) * | 2008-10-14 | 2012-11-27 | Нин Си | Соединения и способы применения |
| KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
| CN102086211B (zh) | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | 作为蛋白激酶抑制剂的芳杂环化合物 |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
-
2013
- 2013-06-29 TW TW102123415A patent/TWI520962B/zh not_active IP Right Cessation
- 2013-07-01 CA CA2878049A patent/CA2878049C/en not_active Expired - Fee Related
- 2013-07-01 BR BR112014032745-9A patent/BR112014032745B1/pt not_active IP Right Cessation
- 2013-07-01 RU RU2015102057A patent/RU2619130C2/ru active
- 2013-07-01 WO PCT/CN2013/078592 patent/WO2014000713A1/en active Application Filing
- 2013-07-01 KR KR1020177003335A patent/KR101726555B1/ko active IP Right Grant
- 2013-07-01 US US14/411,515 patent/US9617257B2/en active Active
- 2013-07-01 KR KR1020177003331A patent/KR101770545B1/ko active IP Right Grant
- 2013-07-01 KR KR1020157002238A patent/KR101726522B1/ko active IP Right Grant
- 2013-07-01 AU AU2013283993A patent/AU2013283993B2/en not_active Ceased
- 2013-07-01 ES ES13809182T patent/ES2698511T3/es active Active
- 2013-07-01 SG SG11201408750VA patent/SG11201408750VA/en unknown
- 2013-07-01 EP EP13809182.2A patent/EP2867223B1/en not_active Not-in-force
- 2013-07-01 JP JP2015518816A patent/JP6059342B2/ja not_active Expired - Fee Related
- 2013-07-01 IN IN372DEN2015 patent/IN2015DN00372A/en unknown
-
2015
- 2015-01-16 ZA ZA2015/00344A patent/ZA201500344B/en unknown
- 2015-08-27 HK HK15108314.5A patent/HK1207642A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2698511T3 (es) | 2019-02-05 |
| BR112014032745A2 (pt) | 2017-06-27 |
| JP6059342B2 (ja) | 2017-01-11 |
| TW201418254A (zh) | 2014-05-16 |
| US9617257B2 (en) | 2017-04-11 |
| CA2878049C (en) | 2016-12-13 |
| KR20170017014A (ko) | 2017-02-14 |
| IN2015DN00372A (ru) | 2015-06-12 |
| EP2867223A1 (en) | 2015-05-06 |
| JP2015521634A (ja) | 2015-07-30 |
| TWI520962B (zh) | 2016-02-11 |
| WO2014000713A1 (en) | 2014-01-03 |
| KR101770545B1 (ko) | 2017-08-22 |
| AU2013283993A1 (en) | 2015-02-05 |
| CA2878049A1 (en) | 2014-01-03 |
| EP2867223A4 (en) | 2016-01-06 |
| KR101726555B1 (ko) | 2017-04-12 |
| BR112014032745B1 (pt) | 2022-01-04 |
| RU2015102057A (ru) | 2016-08-20 |
| EP2867223B1 (en) | 2018-09-05 |
| RU2619130C2 (ru) | 2017-05-12 |
| US20150315210A1 (en) | 2015-11-05 |
| KR20150031320A (ko) | 2015-03-23 |
| ZA201500344B (en) | 2016-08-31 |
| AU2013283993B2 (en) | 2016-07-07 |
| KR20170017015A (ko) | 2017-02-14 |
| SG11201408750VA (en) | 2015-01-29 |
| KR101726522B1 (ko) | 2017-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207642A1 (en) | Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors c-met | |
| HRP20181429T1 (hr) | Novi derivati benzimidazola kao inhibitori kinaze | |
| IL255799B (en) | Converted pyridine-2-carboxamide compounds as inhibitors of apoptosis signal-regulated kinase | |
| HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
| EP2593462A4 (en) | NEW CONDENSED HETEROCYCLIC DERIVATIVES SUITABLE AS C-MET TYROSINE KINASE HEMMER | |
| HK1188145A1 (en) | Novel fused pyridine compounds as casein kinase inhibitors | |
| EP2934525A4 (en) | THIAZOLSUBSTITUTED AMINOPYRIDINE AS MILTSTYROSINKINASE INHIBITOR | |
| HK1258911A1 (zh) | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 | |
| HK1210036A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
| EP2922543A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS | |
| HK1209316A1 (en) | Substituted picolinamide kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220704 |